Inventor · disambiguated record
Jingjing Ji
Also filed as: JI JINGJING
7 granted patents·4 pending applications·15 citations·filing 2018–2024
81Inventor score
Top patents by PatentIndex Score
11 records- 0197US11040036B2Pyruvate kinase activators for use in treating blood disordersAGIOS PHARMACEUTICALS INC·Filed 2020·Granted Jun 22, 2021·7 cites·26 claims
- 0289US11464775B2Pyruvate kinase modulators and use thereofAGIOS PHARMACEUTICALS INC·Filed 2018·Granted Oct 11, 2022·3 cites·21 claims
- 0389US2025144093A1Pyruvate kinase activators for use in treating blood disordersAGIOS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0488US11364240B2Pyruvate kinase activators for use in treating blood disordersAGIOS PHARMACEUTICALS INC·Filed 2018·Granted Jun 21, 2022·4 cites·27 claims
- 0584US12133853B2Pyruvate kinase activators for use in treating blood disordersAGIOS PHARMACEUTICALS INC·Filed 2023·Granted Nov 5, 2024·0 cites·25 claims
- 0681US11957680B2Pyruvate kinase activators for use in treating blood disordersAGIOS PHARMACEUTICALS INC·Filed 2022·Granted Apr 16, 2024·0 cites·14 claims
- 0779US11872225B2Pyruvate kinase modulators and use thereofAGIOS PHARMACEUTICALS INC·Filed 2022·Granted Jan 16, 2024·0 cites·22 claims
- 0879US11590132B2Pyruvate kinase activators for use in treating blood disordersAGIOS PHARMACEUTICALS INC·Filed 2018·Granted Feb 28, 2023·1 cites·24 claims
- 0949US2024109887A1Novel substituted bicyclic aza-heterocycles as sos1 inhibitorsZHANG HONGJIAN·Filed 2022·Application pending·0 cites
- 1048US2022127267A1Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disordersAGIOS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1145US2024109891A1Novel substituted tricyclic aza-heterocycles as sos1 inhibitorsVIVA STAR BIOSCIENCES SUZHOU CO LTD·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jingjing Ji files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →